Novel approaches to treatment of advanced colorectal cancer with anti‐EGFR monoclonal antibodies

References

• Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–30
   PubMed Web of Science ®Google Scholar
• Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first‐line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7
   PubMed Web of Science ®Google Scholar
• Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905–14
   PubMed Web of Science ®Google Scholar
• Kohne C. H., van Cutsem E., Wils J., Bokemeyer C., El‐Serafi M., Lutz M. P., et al. Phase III study of weekly high‐dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856–65
   PubMed Web of Science ®Google Scholar
• Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan‐refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45
   PubMed Web of Science ®Google Scholar
• Herbst R. S., Shin D. M. Monoclonal antibodies to target epidermal growth factor receptor‐positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593–611
   PubMed Web of Science ®Google Scholar
• Meyers M. B., Biedler J. L. Evidence for reverse transformation in multidrug‐resistant human neuroblastoma cells. Prog Clin Biol Res 1988; 271: 449–61
   PubMedGoogle Scholar
• Mayer A., Takimoto M., Fritz E., Schellander G., Kofler K., Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454–60
   PubMed Web of Science ®Google Scholar
• Salomon D. S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor‐related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20 Suppl: 1S–13S
   Web of Science ®Google Scholar
• Goldstein N. I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311–8
   PubMed Web of Science ®Google Scholar
• Arteaga C. L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19 Suppl: 32S–40S
   Web of Science ®Google Scholar
• Fan Z., Masui H., Altas I., Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti‐epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53: 4322–8
   PubMed Web of Science ®Google Scholar
• Bunn P. A Jr., Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non‐small cell lung cancer. Semin Oncol 2002; 29 Suppl 14: 38–44
   Web of Science ®Google Scholar
• Bonner J. A., Raisch K. P., Trummell H. Q., Robert F., Meredith R. F., Spencer S. A., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000; 18 Suppl: 47S–53S
   Web of Science ®Google Scholar
• Prewett M. C., Hooper A. T., Bassi R., Ellis L. M., Waksal H. W., Hicklin D. J. Enhanced antitumor activity of anti‐epidermal growth factor receptor monoclonal antibody IMC‐C225 in combination with irinotecan (CPT‐11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994–1003
   PubMed Web of Science ®Google Scholar
• Saltz L. B., Meropol N. J., Loehrer P. J Sr., Needle M. N., Kopit J., Mayer R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8
   PubMed Web of Science ®Google Scholar
• Lenz H‐J., Mayer R. J., Mirtsching B., Cohn A. L., Pippas A., Windt P., et al. Consistent Response to Treatment with Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer. J Clin Oncol, ASCO Annual Meeting Proceedings part I of II 2005; 23, Abstract 3536
   Google Scholar
• Abubakr Y., Eng C., Pautret V., Maurel J., Scheithauer W., Kroening H. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). J Clin Oncol, ASCO Annual Meeting Proceedings part I 2006; 24, Abstract 3556
   Google Scholar
• Folprecht G., Lutz M. P., Schoffski P., Seufferlein T., Nolting A., Pollert P., et al. Cetuximab and irinotecan/5‐fluorouracil/folinic acid is a safe combination for the first‐line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450–6
   PubMed Web of Science ®Google Scholar
• Rougier P., Raoul J. L., Van Laethem J‐L., Peeters M., Husseini F., Brezault C., et al. Cetuximab+FOLFIRI as first‐line treatment for metastatic colorectal CA. J Clin Oncol, ASCO Annual Meeting Proceedings (Post Meeting Edition) 2004; 22, Abstract 3513
   Google Scholar
• Díaz‐Rubio E., Tabernero J., Van Cutsem E., Cervantes A., André T., Humblet Y., et al. Cetuximab in combination with oxaliplatin/5‐fluorouracil (5‐FU)/folinic acid (FA) (FOLFOX‐4) in the first‐line treatment of patients with epidermal growth factor receptor (EGFR)‐expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol, ASCO Annual Meeting Proceedings, part I of II 2005; 23, Abstract 3535
   Google Scholar
• Seufferlein T., Dittrich C., Riemann J., Woell E., Herrmann T., Lordick F., et al. A phase I/II study of cetuximab in combination with 5‐fluorouracil (5‐FU)/folinic acid (FA) plus weekly oxaliplatin (L‐OHP) (FUFOX) in the first‐line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Part I of II 2005; 23, Abstract 3644
   Google Scholar
• Borner M., Mingrone W., Koeberle D., Von Moos R., Rauch D., Saletti P., et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first‐line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol, ASCO Annual Meeting Proceedings part I 2006; 24, Abstract 3551
   Google Scholar
• Saltz L. B., Lenz H. J., Hochster H., Wadler S., Hoff P., Kemeny N., et al. Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan (CBI) versus Cetuximab/Bevacizumab (CB) in Irinotecan‐Refractory Colorectal Cancer. J Clin Oncol, ASCO Annual Meeting Proceedings part I 2005; 23, Abstract 3508
   Google Scholar
• Matar P., Rojo F., Cassia R., Moreno‐Bueno G., Di Cosimo S., Tabernero J., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC‐C225): superiority over single‐agent receptor targeting. Clin Cancer Res 2004; 10: 6487–501
   PubMed Web of Science ®Google Scholar
• Busam K. J., Capodieci P., Motzer R., Kiehn T., Phelan D., Halpern A. C. Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169–76
   PubMed Web of Science ®Google Scholar
• Erbitux (Cetuximab) package insert. ImClone systems. August 2005, NY, and Bristol‐Myers Squibb, Princeton, NY
   Google Scholar
• Lenz H. J., Mayer R. J., Gold P. J., Mirtsching B., Stella P. J., Cohn A. L., et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol, ASCO Annual Meeting Proceedings (Post Meeting Edition) 2004; 22, Abstract 3510
   Google Scholar
• Chung K. Y., Shia J., Kemeny N. E., Shah M., Schwartz G. K., Tse A., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803–10
   PubMed Web of Science ®Google Scholar
• Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore‐Bianchi A., Di Nicolantonio F., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279–86
   PubMed Web of Science ®Google Scholar
• Lievre A., Bachet J. B., Le Corre D., Boige V., Landi B., Emile J. F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992–5
   PubMed Web of Science ®Google Scholar
• Zhang W., Gordon M., Press O. A., Rhodes K., Vallbohmer D., Yang D. Y., et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16: 475–83
   PubMed Web of Science ®Google Scholar
• Vallbohmer D., Zhang W., Gordon M., Yang D. Y., Yun J., Press O. A., et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536–44
   PubMed Web of Science ®Google Scholar
• Bier H., Hoffmann T., Haas I., van Lierop A. Anti‐(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody‐dependent cell‐mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998; 46: 167–73
   PubMed Web of Science ®Google Scholar
• Zhang W., Gordon M., Schultheis A. M., Nagashima A. M., Azuma M., Yang D., et al. Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR‐expressing metastatic colorectal cancer patients treated with single agent cetuximab. J Clin Oncol, ASCO Annual Meeting Proceedings part I 2006; 24, Abstract 3028
   Google Scholar
• Foon K. A., Yang X. D., Weiner L. M., Belldegrun A. S., Figlin R. A., Crawford J., et al. Preclinical and clinical evaluations of ABX‐EGF, a fully human anti‐epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58: 984–90
   PubMed Web of Science ®Google Scholar
• Yang X. D., Jia X. C., Corvalan J. R., Wang P., Davis C. G. Development of ABX‐EGF, a fully human anti‐EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17–23
   PubMed Web of Science ®Google Scholar
• Malik I., Hecht J. R., Patnaik A., Venook A., Berlin J., Croghan G., et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol, ASCO Annual Meeting Proceedings part I of II 2005; 23, Abstract 3520
   Google Scholar
• Hecht J., Mitchell E., Baranda J., Malik I., Richards D., Navale L., et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006; 24, Abstract 3547
   Google Scholar
• Gibson T. B., Ranganathan A., Grothey A. Randomized phase III trial results of panitumumab, a fully human anti‐epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 29–31
   PubMed Web of Science ®Google Scholar
• Hecht J., Posey J., Tchekmedyian S., Hu E., Chan D., Malik I., et al. Panitumumab in combination with 5‐fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first‐line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol, 2006 Gastrointestinal Cancers Symposium 2006, 2006: Abstract 237
   Google Scholar
• Figlin R. A., Belldegrun A., Crawford J., Lohner M., Roskos L., Yang X. D., et al. ABX‐EGF, a fully human anti‐epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. J Clin Oncol, 2002 ASCO Annual Meeting Proceedings 2002; 21, (Abstract 35)
   Google Scholar
• Hecht J. R., Patnaik A., Malik I., Venook A., Berlin J., Croghan G., et al. ABX‐EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post Meeting Edition) 2004; 22, Abstract 3511
   Google Scholar